{"url_path":"/sec/vbio/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 **","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001437749-26-017142-index.html","accession_number":"0001437749-26-017142","cik":"0001787740","ticker":"VBIO","issuer_name":"Tivic Health Systems, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001437749-26-017142-index.html","primary_entity_key":"0001787740","primary_entity_name":"Valion Bio, Inc."},"word_count":68,"has_tables":true,"body_markdown":"**Item 5.**\n\n**Other Information**\n\n \n\n*Rule 10b5-1 Trading Plans* \n\n \n\nDuring the *three* months ended *March 31, 2026*, none of our directors or officers informed us of any adoption, modification or termination of a “Rule *10b5*-*1* trading arrangement” or “non-Rule *10b5*-*1* trading arrangement,” that were intended to satisfy the affirmative defense conditions of Rule *10b5*-*1,* in each case as defined in Item *408* of Regulation S-K.\n\n \n\n37\n\n[Table of Contents](#toc)"}